Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Kater AP, Kersting S, van Norden Y, Dubois J, Dobber JA, Mellink CH, Evers LM, Croon-de Boer F, Schreurs J, van der Spek E, Visser H, Idink C, Wittebol S, Hoogendoorn M, Tonino SH, Mobasher M, Levin MD; HOVON CLL study group..
Kater AP, et al.
Blood Adv. 2018 Dec 26;2(24):3566-3571. doi: 10.1182/bloodadvances.2018019422.
Blood Adv. 2018.
PMID: 30552161
Free PMC article.